07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C.   Business: Autoimmune, Cardiovascular, Dermatology   Hired: John Barr as CEO, formerly EVP and president of global surgical at Bausch + Lomb Inc. , which Valeant Pharmaceuticals International Inc....
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

MultiStem: Interim Phase II data

Interim data from 88 patients with moderate to severe UC in the efficacy portion of a double-blind, international Phase II trial showed that a single IV infusion of MultiStem missed the co-primary endpoints of improving...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

MultiStem: Completed Phase II enrollment

Athersys said Pfizer completed enrollment in a double-blind, placebo-controlled, international Phase II trial of IV MultiStem. The trial was targeting up to 128 patients. MultiStem is also in Phase II testing to treat ischemic stroke...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Angiotech management update

Angiotech Pharmaceuticals Inc. , Vancouver, B.C.   Business: Autoimmune, Cardiovascular, Dermatology   Transitioned: Thomas Bailey to a director from president and CEO; and Victor Diaz to president and COO from EVP of global manufacturing and...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Angiotech, Argon Medical Devices Inc. deal

Argon Medical Devices Inc. (Athens, Texas) completed the acquisition of Angiotech's Interventional Products Business for $362.5 million in a cash deal. Argon is a portfolio company of private equity firm RoundTable Healthcare Partners (Lake Forest,...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Financial News

Angiotech financial update

Angiotech said it will repurchase $16 million in principal amount of senior floating rate notes, plus accrued and unpaid interest. Following the repurchase, $44 million of the notes will remain outstanding. Angiotech Pharmaceuticals Inc. ,...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Angiotech, RoundTable Healthcare Partners deal

Argon Medical Devices Inc. (Athens, Texas), a portfolio company of private equity firm RoundTable, will acquire Angiotech's Interventional Products Business for $362.5 million in a cash deal. The Interventional Products Business, which manufactures and markets...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Zilver PTX Drug-Eluting Stent regulatory update

FDA approved the Zilver PTX Drug-Eluting Stent from Cook Medical Inc. to treat peripheral artery disease (PAD) in the femoropopliteal artery. The company plans to launch the product in the U.S. early next year. FDA...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Clinical News

Athersys preclinical data

Athersys and partner Fast Forward LLC reported data from a rodent model of MS showing that IV MultiStem given after symptom onset led to sustained, significant improvements in behavior vs. vehicle-treated controls (p<0.0001). MultiStem did...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

MultiStem: Phase II ongoing

Athersys said an independent safety committee recommended continuation to the high dose of MultiStem in a double-blind, placebo-controlled, U.S. Phase II trial based on a review of safety data. The trial is evaluating single doses...